Competing risk data set involving AIDS in women.
A data frame containing:
|time||time to event|
|status||censoring status: 0=censoring, 1=HAART initiation, 2=AIDS/Death before HAART|
|ageatfda||age in years at time of FDA approval of first protease inhibitor|
|idu||history of IDU: 0=no history, 1=history|
|black||race: 0=not African-American; 1=African-American|
|cd4nadir||CD4 count (per 100 cells/ul)|
Study included 1164 women enrolled in WIHS, who were alive, infected with HIV, and free of clinical AIDS on December, 1995, when the first protease inhibitor (saquinavir mesylate) was approved by the Federal Drug Administration. Women were followed until the first of the following occurred: treatment initiation, AIDS diagnosis, death, or administrative censoring (September, 2006). Variables included history of injection drug use at WIHS enrollment, whether an individual was African American, age, and CD4 nadir prior to baseline.
Bacon M.C, von Wyl V., Alden C., et al. (2005). The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench, Clin Diagn Lab Immunol, 12(9):1013-1019.